|
| Status |
Public on Jun 02, 2014 |
| Title |
Gene expression data from medulloblastoma tumor samples |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Smoothened (SMO)-inhibitors recently entered clinical trials for sonic-hedgehog driven medulloblastoma (SHH-MB). Clinical response appears highly variable. To understand the mechanism(s) of primary resistance and to identify pathways co-operating with aberrant SHH-signaling, we sequenced a large cohort of SHH-MBs across all age groups by sequencing, DNA methylation and expression profiling. Our data show that most adults but only half of the pediatric patients with SHH-MB will respond to SMO inhibition as predicted by molecular analysis of the primary tumor and tested in the SHH-xenografts, demonstrating that the next generation of SMO-inhibitor trials should be based on these predictive biomarkers.
To further dissect the biological differences between the different age groups within SHH medulloblastomas, we looked at the transcriptomic profiles of SHH medulloblastoma samples.
|
| |
|
| Overall design |
73 medulloblastoma samples from patients of various ages were selected for RNA extraction and hybridization on Affymetrix Human Genome U133 Plus 2.0 Arrays.
|
| |
|
| Contributor(s) |
Kool M, Pfister S |
| Citation(s) |
24871706, 24651015, 25024229 |
| |
| Submission date |
Jul 26, 2013 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Marcel Kool |
| E-mail(s) |
m.kool@dkfz.de
|
| Organization name |
German Cancer Research Center DKFZ
|
| Department |
Pediatric Neurooncology
|
| Street address |
Im Neuenheimer Feld 280
|
| City |
Heidelberg |
| ZIP/Postal code |
69120 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (73)
|
|
| Relations |
| BioProject |
PRJNA213380 |
Less...
More...